Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 6, 2010, Pages 1029-1037

  Park, Seong Tae ^a   Jang, Jeong Won ^a   Kim, Gi Dae ^a   Park, Joung Ah ^a   Hur, Wonhee ^a   Woo, Hyun Young ^a   Kim, Jin Dong ^a   Kwon, Jeong Hyun ^a   Yoo, Chan Ran ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Angiogenesis; Cyclophosphamide; Hepatocellular carcinoma; Metronomic chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ALKYLATING AGENT; CYCLINE; DIETHYLNITROSAMINE; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; ENDOTHELIUM CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; TUMOR VOLUME; ANIMAL; APOPTOSIS; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG ADMINISTRATION; GENETICS; IMMUNOBLOTTING; KAPLAN MEIER METHOD; LIVER; LIVER TUMOR; METABOLISM; PATHOLOGY; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BODY WEIGHT; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DIETHYLNITROSAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL CELLS; IMMUNOBLOTTING; KAPLAN-MEIERS ESTIMATE; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; PROLIFERATING CELL NUCLEAR ANTIGEN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 77951894015     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1108-4     Document Type: Article

References (33)

1. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22:5093-5107
2. Song TJ, Ip EW, Fong Y (2004) Hepatocellular carcinoma: current surgical management. Gastroenterology 127:248-260
3. Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of lowdose metronomic chemotherapy. Proc Natl Acad Sci USA 100:12917-12922
4. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045-1047
5. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436
6. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drugresistant cancer. Cancer Res 60:1878-1886
7. Gasparini G (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2:733-740
8. Stempak D, Seely D, Baruchel S (2006) Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Invest 24:432-443
9. Giavazzi R, Taraboletti G (1999) Angiogenesis and angiogenesis inhibitors in cancer. Forum (Genova) 9:261-272
10. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674
11. Veikkola T, Alitalo K (1999) VEGFs, receptors and angiogenesis. Semin Cancer Biol 9:211-220
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-248
13. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410
14. Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395
15. Ferrara N, Gerber HP, Le Couter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676
16. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346
17. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS (2002) Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62:2731-2735
18. Stolting S, Klink T, Bela C, Engels C, Wagner T (2004) Metronomic scheduling of trofosfamide chemotherapy in human NSCLC xenografts highly increases therapeutic efficacy compared to conventional scheduling by inhibition of angiogenesis. Int J Clin Pharmacol Ther 42:652-653
19. Lee TY, Kim KT, Han SY (2007) Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver. Korean J Hepatol 13:70-80
20. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clergue F, Poupon R, Barbu V, Rosmorduc O (2005) Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41:307-314
21. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501
22. Pang LP, Huang W, Sun Q, Guo W, Li RT, Cui JR (2008) SLXM-2, a derivative of cyclophosphamide: mechanism of growth inhibition on hepatocarcinoma 22 cells. Anticancer Drugs 19:167-174
23. Lindner G, Botchkarev VA, Botchkareva NV, Ling G, van der Veen C, Paus R (1997) Analysis of apoptosis during hair follicle regression (catagen). Am J Pathol 151:1601-1617
24. Mirkes PE, Little SA (2000) Cytochrome c release from mitochondria of early postimplantation murine embryos exposed to 4-hydroperoxycyclophosphamide, heat shock, and staurosporine. Toxicol Appl Pharmacol 162:197-206
25. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS (2005) Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res 65:7045-7051
26. Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195-1206
27. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin HG, Ziche M, Lanz C, Buttner M, Rziha HJ, Dehio C (1999) A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18:363-374
28. Rahimi N, Dayanir V, Lashkari K (2000) Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEG-FR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 275:16986-16992
29. Veikkola T, Alitalo K (1999) VEGFs, receptors and angiogenesis. Semin Cancer Biol 9:211-220
30. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275-292
31. Raguz S, Yague E (2008) Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 99:387-391
32. Jia LJ, Wei DP, Sun QM, Jin GH, Li SF, Huang Y, Hua ZC (2007) Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. Int J Cancer 121:666-674
33. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V (2003) Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 63:8408-8413